Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation

Objective(s): To investigate the clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of adults with pulmonary arterial hypertension (PAH) within their licensed indications. Data sources: Major electronic databases (including the Cochrane L...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Y-F Chen, S Jowett, P Barton, K Malottki, C Hyde, JSR Gibbs, J Pepke-Zaba, A Fry-Smith, J Roberts, D Moore
Formato: Artigo
Idioma:Inglês
Publicado em: NIHR Journals Library 2009-10-01
Colecção:Health Technology Assessment
Assuntos:
epoprostenol
iloprost
bosentan
sitaxentan
sildenafil
pulmonary-arterial-hypertension
Acesso em linha:https://doi.org/10.3310/hta13490
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados